SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Studies that used rat/mice model with NAFLD/NASH and diabetes found out that the use of SGLT-2 inhibitors was able to decrease de novo lipogenesis and increase fatty acid β-oxidation, therefore improving hepatic steatosis [209].